fludarabine,cyclophosphamide,axicabtagene ciloleucel,lisocabtagene maraleucel
bms,gilead
['liso-cel', 'transform,(-transformi),(-transforme),(-transforma),(-transforms),(-transform1),(-transform 1),(-transform-1),(-transform2),(-transform 2),(-transform-2)', 'lymsm', 'axi-cel', 'cml', 'zuma-7']
with respect to car-t in the second line for lbcl, we now know from #asco23 that axi-cel has superior os to standard care from zuma-7. liso-cel transform data suggests that cr rates are higher when car used in earlier lines (better t-cell product?). #17icml #lymsm cc 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈